Project Covalence

In one sentence

Project Covalence aims to break the bottleneck of slow, expensive clinical trials by providing a shared infrastructure for researchers to run remote, community-based COVID-19 trials.

Why read this (and who it's for)

This is for researchers, pharmaceutical companies, and non-profits involved in developing COVID-19 drugs, vaccines, or diagnostics. It identifies the primary operational bottleneck in medical science—clinical trial execution—and proposes a systemic shift toward shared infrastructure and decentralized trial designs to save time and lives.

The big idea

The author argues that while science is the only way out of the COVID-19 crisis, the current mechanism for delivering that science—clinical trials—is fundamentally broken by its own scale and cost. Trials are currently too time-consuming and expensive, creating a bottleneck that prevents life-saving innovations from reaching the public.

To solve this, Project Covalence proposes a shift from "siloed" trials to a "shared infrastructure" model. Instead of every company building its own bespoke trial system from scratch, researchers can leverage a unified platform (powered by TrialSpark) to run trials in community settings or at a patient's home. This reduces the burden on hospitals while enabling faster, more coordinated data collection.

Key ideas

The Clinical Trial Bottleneck

• What it is — The primary hurdle for companies developing novel drugs, vaccines, and diagnostics is the difficulty of "rapidly spinning up trials."
• Why it matters — Even the best science is useless if it cannot be validated and deployed quickly; the trial process is the gatekeeper of progress.
• In the book — The author notes that "Dramatically improving clinical trials, which are usually time-consuming and cost tens to hundreds of millions of dollars, is one of the highest-leverage ways to get out of [the COVID-19 crisis] faster."

Decentralized Trial Design

• What it is — Moving clinical trials out of hospitals and into community settings or the patient's home.
• Why it matters — It reduces the burden on over-capacity health systems while making it easier for patients to participate.
• In the book — The platform is "uniquely optimized to support COVID-19 trials, which are ideally run in community settings or at the patient’s home."

Shared Infrastructure

• What it is — A shared platform where researchers across academia and industry can leverage the same tools to launch trials.
• Why it matters — It eliminates the need for every individual organization to reinvent the wheel on logistics, data collection, and protocol writing.
• In the book — "Researchers across academia and industry can leverage this shared infrastructure to rapidly launch their clinical trials."

Master Protocols and Shared Control Arms

• What it is — The creation of "master protocols" for platform studies to enable shared control arms and adaptive trial designs.
• Why it matters — This allows different studies to share the same control group, significantly increasing the efficiency and statistical power of multiple trials simultaneously.
• In the book — The project will be "creating master protocols for platform studies to enable shared control arms and adaptive trial designs."

Compliant Remote Data Collection

• What it is — Ensuring that remote data collection and telemedicine are compliant with 21 CFR Part 11.
• Why it matters — Remote data must still meet rigorous regulatory standards to be valid for drug and vaccine approval.
• In the book — The platform supports "21 CFR Part 11 compliant remote data collection, telemedicine, biostatistics, sample kits for at-home specimen collection, and protocol writing."

Frameworks & tools

The project operates on a Shared Infrastructure Model for clinical trials:

1. Platform Access: Utilize a platform powered by TrialSpark specifically optimized for COVID-19.
2. Decentralized Execution: Shift trial locations to community settings or patient homes to reduce hospital burden.
3. Master Protocol Integration: Use shared master protocols to allow for:
   • Shared control arms
   • Adaptive trial designs
4. Full-Stack Support: Leverage the platform for:
   • Protocol writing
   • Biostatistics
   • Sample kits for at-home specimen collection
   • Telemedicine

Memorable examples & stories

The Hospital Burden The author highlights how current trials place a heavy burden on hospitals and health systems. The lesson is that by moving trials to the patient's home, we can preserve hospital capacity for acute care while still advancing science.

The 21 CFR Part 11 Standard The author emphasizes the need for "21 CFR Part 11 compliant remote data collection." The lesson is that "remote" does not mean "less rigorous"—regulatory compliance is the non-negotiable foundation of remote clinical trials.

Key quotes

"Science remains the only way out of the COVID-19 crisis." Why it matters: This establishes the moral and practical imperative for accelerating the trial process.

"Dramatically improving clinical trials... is one of the highest-leverage ways to get out of [the crisis] faster." Why it matters: It identifies the specific "leverage point" where effort yields the greatest systemic change.

"Researchers across academia and industry can leverage this shared infrastructure to rapidly launch their clinical trials." Why it matters: It advocates for a shift from competitive, isolated research to collaborative, infrastructure-based research.

How to apply it

This week

• Identify the Bottleneck: If you are involved in a research project, map out the specific logistical hurdles (e.g., data collection, protocol writing) that are slowing down your progress.
• Audit Remote Capabilities: Review your current data collection methods to see if they meet 21 CFR Part 11 standards for remote reporting.

Ongoing

• Seek Shared Infrastructure: Whenever starting a new trial, ask: "Is there a shared platform or master protocol we can use instead of building this from scratch?"
• Prioritize Decentralization: When designing study protocols, evaluate how many components can be moved from a hospital setting to a community or home setting.

Common pitfalls

• The "More Funding" Fallacy: One might assume that the solution to slow trials is simply more money. The author argues that the solution is better infrastructure and design (shared control arms, master protocols).
• Ignoring Compliance: A common mistake in rapid-response research is neglecting the regulatory requirements (like 21 CFR Part 11) of remote data collection, which can invalidate an entire study.

Connects to

• Decentralized Clinical Trials (DCTs): This project is a specific application of the broader DCT movement.
• Open Source Science: The "shared infrastructure" model mirrors the open-source philosophy of shared resources to accelerate collective progress.

If you remember only three things

• Clinical trials are the primary bottleneck for COVID-19 medical breakthroughs.
• Shared infrastructure (master protocols and shared control arms) can dramatically increase trial efficiency.
• Moving trials to community/home settings reduces hospital burden while maintaining regulatory compliance.

Internalize it

• Reflection questions

  • Where in my current workflow is a "bottleneck" caused by a lack of shared infrastructure?
  • How would my project change if I moved 50% of the data collection to a remote/home setting?
  • Am I trying to "reinvent the wheel" on a process that could be standardized?

• Flashcards Q: What is the primary bottleneck for COVID-19 drugs and vaccines? A: The time-consuming and expensive nature of clinical trials.

Q: What is the goal of Project Covalence? A: To provide better clinical trial support through a shared infrastructure optimized for COVID-19.

Q: How does Project Covalence reduce the burden on hospitals? A: By optimizing trials to be run in community settings or at the patient's home.

Q: What are "master protocols" used for in this project? A: To enable shared control arms and adaptive trial designs.

Q: What regulatory standard does the platform support for remote data? A: 21 CFR Part 11.

Fidelity note

Confidence is high. The summary is strictly based on the provided blog post. The summary covers all logistical supports mentioned (biostatistics, sample kits, etc.) and the specific collaborative model (shared control arms). No information regarding the specific types of drugs or the specific results of the trials was included, as it was not in the source text.